Phase 2 Lymphoma Trial, Recruiting NCT06698484 Sponsor: National University of Malaysia Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06698484
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a type of blood cancer called B cell non-Hodgkin lymphoma (NHL) that has been confirmed by laboratory testing and shown to have a protein called CD19 on the cancer cells
  • People whose cancer did not respond to a second round of treatment, or whose cancer came back after their first treatment when no curative options (such as a stem cell transplant) are available, or whose cancer returned within one year of having their own stem cells transplanted
  • People who have at least one area of cancer that can be measured on a scan, according to standard response guidelines
  • People aged between 13 and 75 years old
  • People whose kidneys, liver, and heart are functioning at an adequate level, as determined by specific blood and heart tests (confirm with trial site)
  • People with blood count results that meet minimum levels for white blood cells, red blood cells, and platelets, as determined by specific blood tests (confirm with trial site)
  • People who are expected to live for more than 12 weeks
  • People who are generally able to carry out daily activities, rated at a level of 2 or below on a standard medical scale of physical fitness (confirm with trial site)
  • Women who could become pregnant must have a negative pregnancy test and must be using two effective methods of contraception
  • Men must be using two effective methods of contraception

Who may not be able to join:

  • People who have lymphoma that is currently active in the brain or spinal cord, detected by imaging or fluid testing
  • People who have another active cancer (other than NHL) or who are currently receiving treatment for another cancer
  • People with severe lung, heart, liver, kidney, or neurological (brain or nerve) problems, including certain heart conditions or uncontrolled high blood pressure
  • People with an active autoimmune disease that requires medication to suppress the immune system
  • People who are HIV positive
  • People with an active Hepatitis B or Hepatitis C infection
  • People with an infection that is not currently under control
  • People who are pregnant or breastfeeding
  • People who have had a stem cell transplant (using their own or a donor's cells) within 12 weeks before joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +60391456450

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
National University of Malaysia
Registry
ClinicalTrials.gov
Start date
3 June 2021
Est. completion
2 June 2025

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

Overall response rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov